70 related articles for article (PubMed ID: 26167871)
1. Epigenetics: Disrupting histone lysine methylation.
Trojer P
Nat Chem Biol; 2015 Aug; 11(8):552-4. PubMed ID: 26167871
[No Abstract] [Full Text] [Related]
2. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
[TBL] [Abstract][Full Text] [Related]
4. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
7. Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction.
Zhong HJ; Lee BR; Boyle JW; Wang W; Ma DL; Hong Chan PW; Leung CH
Chem Commun (Camb); 2016 Apr; 52(34):5788-91. PubMed ID: 27004852
[TBL] [Abstract][Full Text] [Related]
8. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
[TBL] [Abstract][Full Text] [Related]
9. MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency.
Zhang H; Gayen S; Xiong J; Zhou B; Shanmugam AK; Sun Y; Karatas H; Liu L; Rao RC; Wang S; Nesvizhskii AI; Kalantry S; Dou Y
Cell Stem Cell; 2016 Apr; 18(4):481-94. PubMed ID: 26996599
[TBL] [Abstract][Full Text] [Related]
10. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
Wang ZH; Li DD; Chen WL; You QD; Guo XK
Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MLL1 methyltransferase activity suppresses MLL cell growth.
Cancer Discov; 2014 Mar; 4(3):OF21. PubMed ID: 24596216
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
Verma SK; Knight SD
Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of menin-MLL interaction and TGF-β signaling induces replication of human pancreatic beta cells.
Pahlavanneshan S; Behmanesh M; Oropeza D; Furuyama K; Tahamtani Y; Basiri M; Herrera PL; Baharvand H
Eur J Cell Biol; 2020 Jun; 99(5):151094. PubMed ID: 32646642
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
16. ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation.
Minotti R; Andersson A; Hottiger MO
Mol Cell Biol; 2015 Sep; 35(18):3189-99. PubMed ID: 26149390
[TBL] [Abstract][Full Text] [Related]
17. Alkaloid constituents from Viola tianschanica.
Chen QB; Aisa HA
Phytochemistry; 2017 Dec; 144():233-242. PubMed ID: 28985571
[TBL] [Abstract][Full Text] [Related]
18. MLL1 Inhibition and Vitamin D Signaling Cooperate to Facilitate the Expanded Pluripotency State.
Zhang H; Khoa LTP; Mao F; Xu H; Zhou B; Han Y; O'Leary M; Nusrat A; Wang L; Saunders TL; Dou Y
Cell Rep; 2019 Nov; 29(9):2659-2671.e6. PubMed ID: 31775036
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
